Skip to main content

Table 1 Patient characteristics

From: Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease

   IIPs Non-ILD
   UIP + non- UIP IIPs UIP Non-UIP IIPs  
Number of patients 25 12 13 88
Age (year) Median (range) 69 (58–81) 71 (58–80) 68 (60–81) 70 (35–92)
Gender Male (%) 23 (92.0) 12 (100) 11 (84.6) 41 (46.6)
Smoking History Yes (%) 24 (96.0) 12 (100) 12 (92.3) 49 (55.7)
Performance status 0-1 (%) 21 (84.0) 10 (83.3) 11 6) 80 (92.0)
Histology Adenocarcinoma (%) 22 (88.0) 10 (83.3) 12 (92.3) 83 (94.3)
Stage IIIB + IV (%) 19 (76.0) 10 (83.3) 9 (69.2) 73 (82.9)
Line 1/2/3 5/10/10 2/4/6 3/6/4 13/44/31
EGFR mutation Sensitive (%) 3 (12.0) 1 (8.3) 2 (15.3) 28 (31.8)
\